A resolution urging the Food and Drug Administration to review and revise the approval process for experimental drugs.

Declares that it is the sense of the Senate that: (1) the Food and Drug Administration (FDA) is to be commended for its proposed changes to the drug approval process; and (2) the FDA should review the approval process, incorporate ways for more timely, yet safe approval, and for access by all terminally ill patients to experimental drugs awaiting approval.